Key facts
- Egan-Jones recommends voting for Pacira management nominees.
- Egan-Jones recommends voting against DOMA nominees.
- The recommendation concerns the 2026 annual meeting.
Egan-Jones has recommended that shareholders of Pacira BioSciences vote FOR all three management nominees on the BLUE proxy card and AGAINST all three nominees put forward by DOMA Perpetual Capital Management LLC at the 2026 annual meeting. This recommendation aligns with previous assessments from other independent experts like ISS and Glass Lewis, who also found DOMA representation unwarranted. Pacira BioSciences has been actively urging its stockholders to support its slate of directors, warning that the election of DOMA nominees could jeopardize the company's current momentum.